May 22, 2026
May 23, 2026 — closing edition. Let's get straight to what moves your money.
Fact: Nvidia reported $81.6 billion in quarterly revenue, and Bank of America raised its price target to $350.
Verdict: I Would Buy — demand for AI infrastructure shows no signs of slowing, and NVDA remains the "picks and shovels" supplier of this cycle.
Affected: NVDA (direct), AMD, semiconductor sector, major cloud providers (AMZN, MSFT).
Fact: SpaceX filed its IPO paperwork (S-1) and projects a valuation of $1.6 trillion for June 2026.
Verdict: I Would Buy — if you have access to pre-IPO allocations, this is your chance to get into the most disruptive private company on the planet before the open market noise.
Affected: SpaceX (pre-IPO), aerospace sector, satellite suppliers, space insurers.
Fact: The US Department of Commerce allocated $2 billion to quantum computing, among other things, to develop defenses against threats to Bitcoin.
Verdict: I Would Reduce — in the short term, this puts a target on proof-of-work cryptocurrencies; in the long term, it accelerates the obsolescence of current protocols. Reduce exposure to pure BTC.
Affected: BTC (negatively), IONQ (quantum computing), cybersecurity sector, crypto miners.
Fact: The US and Iran have reached a draft agreement that includes a ceasefire and sanctions relief, with direct implications for global trade and the use of crypto in transactions.
Verdict: I Would Buy — sanctions relief unlocks oil flows and reduces geopolitical tensions, benefiting risk assets, especially if the deal allows for greater crypto adoption as a medium of exchange.
Affected: Oil companies (XOM, CVX), defense sector (under pressure), payment-focused cryptocurrencies (XRP, USDC), emerging market ETFs.
Fact: Acelen Renováveis has started building a $1.5 billion biorefinery in Bahia to produce 1 billion liters/year of SAF (sustainable aviation fuel) and green diesel.
Verdict: I Would Buy — this move solidifies Brazil as a global biofuels hub; it's a clear tailwind for the bioenergy sector and agricultural logistics.
Affected: Bioenergy stocks (RAIZ4, CBIO), sugarcane sector, industrial infrastructure builders, airlines (potential cost hedge).
Fact: ApolloBio, INOVIO's Chinese partner, reported positive Phase 3 results for VGX-3100, a DNA immunotherapy for cervical dysplasia.
Verdict: I Would Hold — the result is encouraging, but INO is still far from generating meaningful revenue; worth holding for the next regulatory catalyst, but without adding to the position.
Affected: INO, DNA/RNA biotech sector, women's oncology, Chinese biotech partners.
Ivar recommends Swissquote bank for your international investments. By opening your account through the link below and trading 5 lots or more, you will receive $200 to use on Ivar AI and activate your subscription. Take advantage of this exclusive offer available today!
Offer available for you who have not yet opened your account at Swissquote.
Services available globally except for the following countries: Algeria, Belgium, Canada, China, North Korea, USA, France, Hong Kong, Iran, Iraq, Nigeria, Singapore, Syria, Turkey and Zimbabwe.